Skip to main content
SpringerLink
Log in

Evaluation of New Treatments for Meningococcal Disease

  • Protocol
Meningococcal Disease

Part of the book series: Methods in Molecular Medicine™ ((MIMM,volume 67))

Abstract

It is recognized that improvement in the practice of clinical medicine, including confirmation of the safety and efficacy of some current interventions, depends greatly on the pursuit of appropriate research. It therefore follows that improved clinical care of children depends on their participation in pediatric research. Furthermore, in the absence of relevant research, harm to children may result. Thus formal studies of therapeutic modalities in children is seen as a moral imperative to ensure that children have equal and safe access to existing and new agents (1).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Protocol
USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. American Academy of Pediatrics, Committee on Drugs (1995) Guidelines for the ethical conduct of studies to evaluate drugs in pediatric populations. Pediatrics 95,287.

    Google Scholar 

  2. Platt M. (1997) Child Health statistical review. Arch. Dis. Child. 77, 542–548.

    CAS  PubMed  Google Scholar 

  3. Steven N. and Wood M. (1995) The clinical spectrum of meningococcal disease, in “Meningococcal Disease” (Cartwright K. A. V., ed.), John Wiley and Sons, Chichester, UK, pp. 177–205.

    Google Scholar 

  4. Opal S. M. and Cross A. S. (1999) Clinical trials for severe sepsis: Past failures and future hopes. Infect. Dis. Clin. North Amer. 13, 285–299.

    CAS  Google Scholar 

  5. Rowell M. and Zlotkinm S. (1997) The ethical boundaries of drug research in pediatrics. Pediatr. Clin. North Amer. 44,27–40.

    CAS  Google Scholar 

  6. Brandtzaeg P., Kierulf P., Gaustad P., Skulberg A., Bruun J. N., Halvorsen S., et al. (1989) Plasma endotoxin as a predictor of multiple organ failure and death in systemic meningococcal disease. J. Infect. Dis. 159,195–204.

    CAS  PubMed  Google Scholar 

  7. Mehta N., Nadel S., Booy R., Galassin R., Morrisson A., and Levin M. (2000) Reduction in case fatality rate for meningococcal disease associated with improved healthcare delivery. Pediatr. Res. 47(4), 271 A.

    Google Scholar 

  8. Pollack M. M., Alexander S. R., Clarke N., Ruttimann U. E., Tesselaar H. M., and Bachulis A. C. 1991. Improved outcomes from tertiary center pediatric intensive care: a statewide comparison of tertiary and nontertiary care facilities. Crit. Care Med. 19,150–159.

    Google Scholar 

  9. Derkx B., Wittes J., McCloskey R., and the European Paediatric Meningococcal Septic Shock Trial Study Group(1999) Randomized placebo-controlled trial of HA-1 A, a human monoclonal antibody to endotoxin, in children with meningococcal septic shock. Clin. Infect. Dis. 28,770–777.

    CAS  PubMed  Google Scholar 

  10. Harth S. and Thong Y. (1995) Parental perceptions and attitudes about informed consent in clinical research involving children. Soc. Sci. Med. 40, 1573–1577.

    CAS  PubMed  Google Scholar 

  11. Nadel S., Levin M., and Habibi P. (1995) Treatment of meningococcal disease in childhood, in Meningococcal Disease (Cartwright, K. A. V., ed.), John Wiley and Sons, Chichester, UK, pp. 208–243.

    Google Scholar 

  12. Braude A. I., Douglas H., and Davis C. E. (1973) Treatment and prevention of intravascular coagulation with antiserum to endotoxin. J. Infect. Dis. 128, S157.

    Google Scholar 

  13. McCabe W. R. (1972) Immunization with R mutants of S. minnesota. I. Protection against challenge with heterologous gram-negative bacilli. J. Immunol. 108,601–610.

    CAS  PubMed  Google Scholar 

  14. McCabe W. R., DeMaria A., Jr., Berberich H., and Johns M. A. (1988) Immunization with rough mutants of Salmonella minnesota: Protective activity of IgM and IgG antibody to the R595 (Re chemotype) mutant. J. Infect. Dis. 158,291–300.

    CAS  PubMed  Google Scholar 

  15. Zieglere J., McCutchan J. A., Fierer J., Glauser M. P., Sadoff J. C., Douglas H., and Braude A. I. (1982) Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli. N. Engl. J. Med. 307,1225–1230.

    Google Scholar 

  16. Warren H. S., Amato S. F., Fitting C., Black K. M., Loiselle P. M., Pasternack M. S., and Cavaillon J. M. (1993) Assessment of ability of murine and human anti-lipid A monoclonal antibodies to bind and neutralize lipopolysaccharide. J. Exp. Med. 177, 89–97.

    CAS  PubMed  Google Scholar 

  17. Chan B., Kalabalikis P., Klein N., Heyderman R., and Levin M. (1996) Assessment of the effect of candidate anti-inflammatory treatments on the interaction between meningococci and inflammatory cells in vitro in a whole blood model. Biotherapy 9, 221–228.

    CAS  PubMed  Google Scholar 

  18. McCloskey R. V., Straube R. C., Sanders C., Smith S. M., and Smith C. R. (1994) Treatment of septic shock with human monoclonal antibody HA-1A. A randomized, double-blind, placebo-controlled trial. CHESS Trial Study Group. Ann. Intern. Med. 121, 1–5.

    CAS  PubMed  Google Scholar 

  19. Angus D. C., Birmingham M. C., Balk R. A., Scannon P. J., Collins D., Kruse J. A., et al. (2000) E5 murine monoclonal antiendotoxin antibody in gram-negative sepsis: a randomized controlled trial. E5 Study Investigators. JAMA 283,1723–1730.

    CAS  PubMed  Google Scholar 

  20. Hailman E., Lichenstein H. S., Wurfel M. M., Miller D. S., Johnson D. A., Kelley M., et al. (1994) Lipopolysaccharide (LPS)-binding protein accelerates the binding of LPS to CD14. J. Exp. Med. 179, 269–277.

    CAS  PubMed  Google Scholar 

  21. Gazzano-Santoro H., Parent J. B., Grinna L., Horwitz A., Parsons T., Theofan G., et al. (1992) High-affinity binding of the bactericidal/permeability-increasing protein and a recombinant amino-terminal fragment to the lipid A region of lipopolysaccharide. Infect. Immun. 60,4754–4761.

    CAS  PubMed  Google Scholar 

  22. Larrick J. W., Hirata M., Zheng H., Zhong J., Bolin D., Cavaillon J. M., et al. (1994) A novel granulocyte-derived peptide with lipopolysaccharide-neutralizing activity.J. Immunol. 152, 231–240.

    CAS  PubMed  Google Scholar 

  23. Giroir B. P., Quint P. A., Barton P., Kirsch E. A., Kitchen L., Goldstein B., et al. (1997) Preliminary evaluation of recombinant amino-terminal fragment of human bactericidal/permeability-increasing protein in children with severe meningococcal sepsis. Lancet 350,1439–1443.

    CAS  PubMed  Google Scholar 

  24. Levin M., Quint P. A., Goldstein B., Barton P., Bradley J. S., Shemie S. D., Yeh T., Kim S. S., Cafaro D. P., Scannon P. J., Giroir B. P., and the BPI21 Meningococcal Sepsis Study Group(2000) Recombinant bactericidal/permeabilityincreasing protein(rBPI21) as adjunctive treatment for children with severe meningococcal sepsis: a randomised trial. Lancet 356, 961–967.

    CAS  PubMed  Google Scholar 

  25. Hellman J. and Warren H. S. (1999) Antiendotoxin strategies. Infect. Dis. Clin. N. Amer. 13, 371–386.

    CAS  Google Scholar 

  26. Parker T. S., Levine D. M., Chang J. C., Laxer J., Coffin C. C., and Rubin A. L. (1995) Reconstituted high-density lipoprotein neutralizes gram-negative bacterial lipopolysaccharides in human whole blood. Infect. Immun. 63,253–258.

    CAS  PubMed  Google Scholar 

  27. Pajkrt D., Doran J. E., Koster F., Lerch P. G., Arnet B., van der Poll T., et al. (1996) Antiinflammatory effects of reconstituted high-density lipoprotein during human endotoxemia. J. Exp. Med. 184,1601–1608.

    CAS  PubMed  Google Scholar 

  28. Alpert G., Baldwin G., Thompson C., Wainwright N., Novitsky T. J., Gillis Z., et al. (1992) Limulus antilipopolysaccharide factor protects rabbits from meningococcal endotoxin shock. J. Infect. Dis. 165,494–500.

    CAS  PubMed  Google Scholar 

  29. Fletcher M. A., McKenna T. M., Quance J. L., Wainwright N. R., and Williams T. J. (1993) Lipopolysaccharide detoxification by endotoxin neutralizing protein. Surg. Res. 55,147–154.

    CAS  Google Scholar 

  30. Roth R. I., Su D., Child A. H., Wainwright N. R., and Levin J. (1998) Limulus antilipopolysaccharide factor prevents mortality late in the course of endotoxemia. J. Infect. Dis. 177, 388–394.

    CAS  PubMed  Google Scholar 

  31. Gardlund B., Sjolin J., Nilsson A., Roll M., Wickerts C. J., Wikstrom B., and Wretlind B. (1993) Plasmapheresis in the treatment of primary septic shock in humans. Scand. J. Infect. Dis. 25,757–761.

    CAS  PubMed  Google Scholar 

  32. Hoffmann J. N., Hartl W. H., Deppisch R., Faist E., Jochum M., and Inthorn D. (1995) Hemofiltration in human sepsis: evidence for elimination of immunomodulatory substances. Kidney Int. 48,1563–1570.

    CAS  PubMed  Google Scholar 

  33. Pollack M. (1992) Blood exchange and plasmapheresis in sepsis and septic shock. Clin. Infect. Dis. 15,431–433.

    CAS  PubMed  Google Scholar 

  34. Aoki H., Kodama M., Tani T., and Hanasawa K. (1994) Treatment of sepsis by extracorporeal elimination of endotoxin using polymyxin B-immobilized fiber. Am. J. Surg. 167,412–417.

    CAS  PubMed  Google Scholar 

  35. Ronco C., Bellomo R., Homel P., Brendolan A., Dan M., Piccinni P., and La Greca G. (2000) Effects of different doses in continuous veno-venous haemofiltration on outcomes of acute renal failure: a prospective randomised trial. Lancet 356,26–30.

    CAS  PubMed  Google Scholar 

  36. Reeves J. H., Butt W. W., Shann F., Layton J. E., Stewart A., Waring P. M., and Presneill J. J. (1999) Continuous plasmafiltration in sepsis syndrome. Plasmafiltration in Sepsis Study Group. Crit. Care Med. 27, 2096–2104.

    CAS  PubMed  Google Scholar 

  37. van Deuren M., Frieling J. T., yvan der Ven-Jongekrijg J., Neeleman C., Russel F. G., van Lier H. J., et al. (1998) Plasma patterns of tumor necrosis factor-alpha (TNF) and TNF soluble receptors during acute meningococcal infections and the effect of plasma exchange. Clin. Infect. Dis. 26,918–923.

    PubMed  Google Scholar 

  38. Kawata T., Bristol J. R., Rossignol D. P., Rose J. R., Kobayashi S., Yokohama H., et al. (1999). E5531, a synthetic non-toxic lipid A derivative blocks the immunobiological activities of lipopolysaccharide. Br. J. Pharmacol. 127, 853–862.

    CAS  PubMed  Google Scholar 

  39. Salkowski C. A., Detore G., Franks A., Falk M. C., and Vogel S. N. (1998) Pulmonary and hepatic gene expression following cecal ligation and puncture: monophosphoryl lipid A prophylaxis attenuates sepsis-induced cytokine and chemokine expression and neutrophil infiltration. Infect. Immun. 66, 3569–3578.

    CAS  PubMed  Google Scholar 

  40. Waage A., Brandtzaeg P., Halstensen A., Kierulf P., and Espevik T. (1989) The complex pattern of cytokines in serum from patients with meningococcal septic shock.J. Exp. Med. 169, 333–338.

    CAS  PubMed  Google Scholar 

  41. van der Poll T. and van Deventer S. J. H. (1999) Cytokines and anticytokines in the pathogenesis of sepsis. Infect. Dis. Clin. North Amer. 13,413–426.

    Google Scholar 

  42. Bone R. C., Grodzin C. J., and Balk R. A. (1997) Sepsis: a new hypothesis for pathogenesis of the disease process. Chest 112,235–243.

    CAS  PubMed  Google Scholar 

  43. Lowry S. F., Calvano S. E., and van der Poll T. (1995) Measurement of inflammatory mediators in clinical sepsis, in Clinical Trials for the Treatment of Sepsis (Sibbald W. J. and Vincent J. L., eds.), Springer-Verlag, New York, pp 86–112.

    Google Scholar 

  44. Marchant A., Deviere J., Byl B., De Groote D., Vincent J. L., and Goldman M. (1994) Interleukin-10 production during septicaemia. Lancet 343,707–708.

    CAS  PubMed  Google Scholar 

  45. van Deuren M., van der Ven-Jongekrijg J., Demacker P. N., Bartelink A. K., van Dalen R., Sauerwein R. W., et al. (1994) Differential expression of proinflammatory cytokines and their inhibitors during the course of meningococcal infections. J. Infect. Dis. 169, 157–161.

    PubMed  Google Scholar 

  46. Docke W. D., Randow F., Syrbe U., Krausch D., Asadullah K., Reinke P., et al. (1997) Monocyte deactivation in septic patients: restoration by IFN-gamma treatment. Nat. Med. 3, 678–681.

    CAS  PubMed  Google Scholar 

  47. Fisher C. J., Jr, Agosti J. M., Opal S. M., Lowry S. F., Balk R. A., Sadoff J. C., et al. (1996) Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. N. Engl. J. Med. 334, 1697–1702.

    CAS  PubMed  Google Scholar 

  48. Parent C. and Eichacker P. Q. (1999) Neutrophil and endothelial cell interactions in sepsis. Infect. Dis. Clin, North Amer. 13,427–447.

    CAS  Google Scholar 

  49. Hawkins H. K., Heffelfinger S. C., and Anderson D. C. (1992) Leukocyte adhesion deficiency: Clinical and post-mortem observations. Pediatr. Pathol. Lab. Med. 12,119–130.

    CAS  Google Scholar 

  50. Eichacker P. Q., Hoffman W. D., Farese A., Danner R. L., Suffredini A. F., Waisman Y., et al. (1992) Leukocyte CD18 monoclonal antibody worsens endotoxemia and cardiovascular injury in canines with septic shock. J. Appl. Physiol. 74,1885–1892.

    Google Scholar 

  51. Friedman G., Jankowski S., Shahla M., Goldman M., Rose R. M., Kahn R. J., and Vincent J. L. (1996) Administration of an antibody to E-Selectin in patients 52. Moncada, S. and Higgs, A. (1993) The L-arginine nitric oxide pathway. N. Engl. J. Med. 329,2002–2012.

    Google Scholar 

  52. Cobb J. P. and Danner R. L. (1996) Nitric oxide and septic shock. JAMA 275, 1192–1196.

    CAS  PubMed  Google Scholar 

  53. Murad F. (1996) Signal transduction using nitric oxide and cyclic guanosine monophosphate. JAMA 276, 1189–1192.

    CAS  PubMed  Google Scholar 

  54. Avontuur J. A., Boomsma F., van den Meiracker A. H., de Jong F. H., and Bruining H. A. (1999) Endothelin-1 and blood pressure after inhibition of nitric oxide synthesis in human septic shock. Circulation 99, 271–275.

    CAS  PubMed  Google Scholar 

  55. Baines P. B., Stanford S., Bishop-Bailey D., Sills J. A., Thomson A. P., Mitchell J. A., et al. (1999) Nitric oxide production in meningococcal disease is directly related to disease severity. Crit. Care Med. 27, 1187–1190.

    CAS  PubMed  Google Scholar 

  56. Avontuur J. A., Tutein Nolthenius R. P., Buijk S. L., Kanhai K. J., and Bruining H. A. (1998) Effect of L-NAME, an inhibitor of nitric oxide synthesis, on cardiopulmonary function in human septic shock. Chest 113, 1640–1646.

    CAS  PubMed  Google Scholar 

  57. Parrillo J. E., Burch C., Shelhamer J. H., Parker M. M., Natanson C., and Schuette W. (1985) A circulating myocardial depressant substance in humans with septic shock. Septic shock patients with a reduced ejection fraction have a circulating factor that depresses in vitro myocardial cell performance. J. Clin. Invest. 76,1539–1553.

    CAS  PubMed  Google Scholar 

  58. Hare J. M. and Colucci W. S. (1995) Role of nitric oxide in the regulation of myocardial function. Prog. Cardiovasc. Dis. 38,155–166.

    CAS  PubMed  Google Scholar 

  59. Kumar A., Kosuri R., Thota V., et al. (1993) Nitric oxide and cGMP generation mediates human septic serum induced in vitro cardiomyocyte depression. Chest 104, 12S.

    Google Scholar 

  60. Kumar A. and Thora V. (1995) Tumor necrosis factor impairs epinephrine stimulated cardiomyocyte contractility and cyclic AMP response through a nitric oxide independent mechanism. Crit. Care Med. 23, A148.

    Google Scholar 

  61. Cobb J. P., Natanson C., Hoffman W. D., Lodato R. F., Banks S., Koev C. A., et al. (1992) N omega-amino-L-arginine, an inhibitor of nitric oxide synthase, raises vascular resistance but increases mortality rates in awake canines challenged with endotoxin. J. Exp. Med. 176,1175–1182.

    CAS  PubMed  Google Scholar 

  62. Freeman B. D. and Cobb J. P. (1998) Nitric oxide synthase as a therapeutic target in sepsis-more questions than answers? Crit. Care Med. 26,1146–1147.

    Google Scholar 

  63. Hollenberg S. M. (1998) A yellow light for nitric oxide synthase inhibitors in sepsis: Proceed with caution. Crit. Care Med. 26, 815–816.

    CAS  PubMed  Google Scholar 

  64. Avontuur J. A., Biewenga M., Buijk S. L., Kanhai K. J., and Bruining H. A. (1998) Pulmonary hypertension and reduced cardiac output during inhibition of nitric oxide synthesis in human septic shock. Shock 9,451–454.

    CAS  PubMed  Google Scholar 

  65. Jourdain M., Tournoys A., Leroy X., Mangalaboyi J., Fourrier F., Goudemand J., et al. (1997) Effects of N omega-nitro-L-arginine methyl ester on the endotoxin-induced disseminated intravascular coagulation in porcine septic shock. Crit. Care Med. 25,452–459.

    CAS  PubMed  Google Scholar 

  66. Kiehl M. G., Ostermann H., Meyer J., and Kienast J. (1997) Nitric oxide synthase inhibition by L-NAME in leukocytopenic patients with severe septic shock. Intensive Care Med. 23, 561–566.

    CAS  PubMed  Google Scholar 

  67. Grover R., Lopez A., Lorente J., et al. (1999) Multicenter, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: effect on survival in patients with septic shock. Crit. Care Med. 27, A33.

    Google Scholar 

  68. Rosselet A., Feihl F., Markert M., Gnaegi A., Perret C., and Liaudet L. (1998) Selective iNOS inhibition is superior to norepinephrine in the treatment of rat endotoxic shock. Am. J. Respir. Crit. Care Med. 57,162–170.

    Google Scholar 

  69. Perrella M. A., Hsieh C. M., Lee W. S., Shieh S., Tsai J. C., Patterson C., et al. (1996) Arrest of endotoxin-induced hypotension by transforming growth factor beta1. Proc. Natl. Acad. Sci. USA 93,2054–2059.

    CAS  PubMed  Google Scholar 

  70. Brandtzaeg P. (1995) Pathogenesis of meningococcal infections, in Meningococcal Disease (Cartwright K. A. V., ed.), John Wiley and Sons, Chichester, UK, pp.177–205.

    Google Scholar 

  71. Hermans P. W., Hibberd M. L., Booy R., Daramola O., Hazelzet J. A., de Groot R., and Levin M. (1999) 4G/5G promoter polymorphism in the plasminogen-activator-inhibitor-1 gene and outcome of meningococcal disease. Meningococcal Research Group. Lancet 354,556–560.

    CAS  PubMed  Google Scholar 

  72. Esmon C. T., Taylor F. B., and Snow R. T. (1991) Inflammation and coagulation: linked processes potentially regulated through a common pathway mediated by protein C. Thromb. Haemost. 66,160–165.

    CAS  PubMed  Google Scholar 

  73. Comp P. C., Nixon R. R., Cooper M. R., and Esmon C. T. (1984) Familial protein S deficiency is associated with recurrent thrombosis. J. Clin. Invest. 74, 2082–2088.

    CAS  PubMed  Google Scholar 

  74. Heyderman R. S., Klein N. J., Shennan G. I., and Levin M. (1992) Modulation of the anticoagulant properties of glycosaminoglycans on the surface of the vascular endothelium by endotoxin and neutrophils: evaluation by an amidolytic assay. Thromb. Res. 67,677–685.

    CAS  PubMed  Google Scholar 

  75. Gérard P., Moriau M., Bachy A., Malvaux P., and De Meyer R. (1973) Meningococcal purpura: report of 19 patients treated with heparin. J. Pediatr. 82,780–786.

    PubMed  Google Scholar 

  76. Corrigan J. J. and Jordan C. M. (1970) Heparin therapy in septicemia with disseminated intravascular coagulation. N. Engl. J. Med. 283, 778.

    PubMed  Google Scholar 

  77. Taylor F. B., Jr, Chang A., Esmon C. T., D′Angelo A., Vigano-D′Angelo S., and Blick K. E. (1987) Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon. J. Clin. Invest. 79,918–925.

    CAS  PubMed  Google Scholar 

  78. Smith O. P., White B., Vaughan D., Rafferty M., Claffey L., Lyons B., and Casey W. (1997) Use of protein-C concentrate, heparin, and haemodiafiltration in meningococcus-induced purpura fulminans. Lancet 350,1590–1593.

    CAS  PubMed  Google Scholar 

  79. Rintala E., Seppala O. P., Kotilainen P., Pettila V., and Rasi V. (1998) Protein C in the treatment of coagulopathy in meningococcal disease. Crit. Care Med. 26, 965–968.

    CAS  PubMed  Google Scholar 

  80. Clarke R. C., Johnston J. R., and Mayne E. E. (2000) Meningococcal septicaemia: treatment with protein C concentrate. Intensive Care Med. 26,471–473.

    CAS  PubMed  Google Scholar 

  81. Bernard G. R., Vincent J-L., Laterre P-F., et al. (2001) Efficacy and safety of recombinant human activated protein C for severe sepsis. N. Engl. J. Med. 344,699–709.

    CAS  PubMed  Google Scholar 

  82. Fourrier F., Chopin C., Huart J. J., Runge I., Caron C., and Goudemand J. (1993) Double-blind, placebo-controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation. Chest 104, 882–888.

    CAS  PubMed  Google Scholar 

  83. Baudo F., Caimi T. M., de Cataldo F., Ravizza A., Arlati S., Casella G., et al. (1998) Antithrombin III (ATIII) replacement therapy in patients with sepsis and/or postsurgical complications: a controlled double-blind, randomized, multicenter study. Intensive Care Med. 24, 336–342.

    CAS  PubMed  Google Scholar 

  84. Taylor F. B., Jr, Chang A., Ruf W., Morrissey J. H., Hinshaw L., Catlett R., et al. (1991) Lethal E. coli septic shock is prevented by blocking tissue factor with monoclonal antibody. Circ. Shock. 33, 127–134.

    PubMed  Google Scholar 

  85. Creasey A. A., Chang A. C., Feigen L., Wun T. C., Taylor F.B., Jr, and Hinshaw L. B. (1993) Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock. J. Clin. Invest. 91,2850–2856.

    CAS  PubMed  Google Scholar 

  86. Goldfarb R. D., Glock D., Johnson K., Creasey A. A., Carr C., McCarthy R. J., et al. (1998) Randomized, blinded, placebo-controlled trial of tissue factor pathway inhibitor in porcine septic shock. Shock 10,258–264.

    CAS  PubMed  Google Scholar 

  87. Zenz W., Muntean W., Gallistl S., Zobel G., and Grubbauer H. M. (1995) Recombinant tissue plasminogen activator treatment in two infants with fulminant meningococcemia. Pediatrics 96,44–48.

    Google Scholar 

  88. Aiuto L. T., Barone S. R., Cohen P. S., and Boxer R. A. (1997) Recombinant tissue plasminogen activator restores perfusion in meningococcal purpura fulminans. Crit. Care Med. 25, 1079–1082.

    CAS  PubMed  Google Scholar 

  89. Murakami J., Ohtani A., and Murata S. (1997) Protective effect of T-686, an inhibitor of plasminogen activator inhibitor-1 production, against the lethal effect of lipopolysaccharide in mice. Jpn. J. Pharmacol. 75,291–294.

    CAS  PubMed  Google Scholar 

  90. Cochrane Injuries Group Albumin Reviewers (1998) Human albumin administration in critically ill patients: systematic review of randomised controlled trials. BMJ 235–240.

    Google Scholar 

  91. Oragui E. E, Nadel S., Kyd P., and Levin M. (2000) Increased excretion of glycosaminoglycans in meningococcal septicaemia and their relationship to proteinuria. Crit. Care Med. 28, In press.

    Google Scholar 

  92. Stewart D. L., Dela Cruz T. V., Ziegler C., and Goldsmith L. J. (1997) The use of extracorporeal membrane oxygenation in patients with gram-negative or viral sepsis. Perfusion 12, 3–8.

    CAS  PubMed  Google Scholar 

  93. Meyer D. M. and Jessen M. E. (1997) Results of extracorporeal membrane oxygenation in children with sepsis. The Extracorporeal Life Support Organization. Ann. Thorac. Surg. 63,756–761.

    CAS  PubMed  Google Scholar 

  94. Goldman A. P., Kerr S. J., Butt W., Marsh M. J., Murdoch I. A., Paul T., et al. (1997) Extracorporeal support for intractable cardiorespiratory failure due to meningococcal disease. Lancet 349,466–469.

    CAS  PubMed  Google Scholar 

  95. Beca J. and Butt W. (1994) Extracorporeal membrane oxygenation for refractory septic shock in children. Pediatrics 93,726–729.

    CAS  PubMed  Google Scholar 

  96. Lebel M. H., Freij B. J., Syrogiannopoulos G. A., Chrane D. F., Hoyt M. J., Stewart S. M., et al. (1988) Dexamethasone therapy for bacterial meningitis. Results of two double-blind, placebo-controlled trials. N. Engl. J. Med. 319,964–971.

    CAS  PubMed  Google Scholar 

  97. Odio C. M., Faingezicht I., Paris M., Nassar M., Baltodano A., Rogers J., et al. (1991) The beneficial effects of early dexamethasone administration in infants and children with bacterial meningitis. N. Engl. J. Med. 324, 525–531.

    Google Scholar 

  98. Hatherill M., Tibby S. M., Hilliard T., Turner C., and Murdoch I. A. (1999) Adrenal insufficiency in septic shock. Arch. Dis. Child. 80, 51–55.

    CAS  PubMed  Google Scholar 

  99. Riordan F. A., Thomson A. P., Ratcliffe J. M., Sills J. A., Diver M. J., and Hart C. A. (1999) Admission cortisol and adrenocorticotrophic hormone levels in children with meningococcal disease: evidence of adrenal insufficiency? Crit. Care Med. 27, 2257–2261.

    CAS  PubMed  Google Scholar 

  100. Briegel J., Forst H., Haller M., Schelling G., Kilger E., Kuprat G., et al. (1999) Stress doses of hydrocortisone reverse hyperdynamic septic shock: a prospective, randomized, double-blind, single-center study. Crit. Care Med. 27,723–732.

    CAS  PubMed  Google Scholar 

  101. Cronin L., Cook D. J., Carlet J., Heyland D. K., Math D. K., Lansang M. A. D., and Fisher C. J., Jr. (1995) Corticosteroid treatment for sepsis: a critical appraisal and meta-analysis of the literature. Crit. Care Med. 23, 1430–1439.

    CAS  PubMed  Google Scholar 

  102. Westendorp R. G., Langermans J. A., Huizinga T. W., Elouali A. H., Verweij C. L., Boomsma D. I., et al. (1997) Genetic influence on cytokine production and fatal meningococcal disease. Lancet 349,170–173.

    CAS  PubMed  Google Scholar 

  103. Nadel S., Newport M. J., Booy R., and Levin M. (1996) Variation in the tumor necrosis factor-alpha gene promoter region may be associated with death from meningococcal disease. J. Infect. Dis. 174, 878–880.

    CAS  PubMed  Google Scholar 

  104. Angus D. C., Birmingham M. C., Balk R. A., Scannon P. J., Collins D., Kruse J. A., et al. (2000) E5 murine monoclonal anti-endotoxin antibody in gram-negative sepsis: a randomised controlled trial. E5 Study Investigators. JAMA 283, 1723–1730.

    CAS  PubMed  Google Scholar 

  105. Asai Y., Nozo Y., Ikeuchi T., Narazaki R., Iwamoto K., and Watanabe S. (1999) The effect of Lipid A analog E5531 on fever induced by endotoxin from Escherichia Coli. Biol. Pharmaceut. Bull. 22, 432–434.

    CAS  Google Scholar 

  106. Haupt M. T., Jastremski M. S., Clemmer T. P., Metz C. A., and Goris G. B. (1991) Effect of ibuprofen in patients with severe sepsis: a randomized, double-blind, multicenter study. The Ibuprofen Study Group. Crit. Care Med. 19,1339–1347.

    CAS  PubMed  Google Scholar 

  107. Opal S. M., Fisherm C. J., Jr., Dhainaut J. F., Vincent J. L., Brase R., Lowry S. F., et al. (1997) Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group. Crit. Care Med. 25, 1115–1124.

    CAS  PubMed  Google Scholar 

  108. Cohen J. and Carlet J. INTERSEPT: an international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis. International Sepsis Trial Study Group. Crit. Care Med. 24, 1431–1440.

    Google Scholar 

  109. Dhainaut J. F., Tenaillon A., Hemmer M., Damas P., Le Tulzo Y., Radermacher P., et al. (1998) Confirmatory platelet-activating factor receptor antagonist trial in patients with severe gram-negative bacterial sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. BN 52021 Sepsis Investigator Group. Crit. Care Med. 26, 1963–1971.

    CAS  PubMed  Google Scholar 

  110. Soltys J. and Quinn M. T. (1999) Modulation of endotoxin and enterotoxin-induced cytokine release by in vivo treatment with beta-(1,6)-branched beta-(1,3)-glucan. Infect. Immun. 67, 244–252.

    CAS  PubMed  Google Scholar 

  111. Olszyna D. P., Pajkrt D., Lauw F. N., van Deventer S. J., and van Der Poll T. (2000) Interleukin 10 inhibits the release of CC chemokines during human endotoxemia. J. Infect. Dis. 181, 613–620.

    CAS  PubMed  Google Scholar 

  112. Opal S. M., Jhung J. W., Keith J. C., Jr., Perlandy J. E., Parejo N. A., Young L. D., and Bhattacharjee A. (1998) Recombinant human interleukin 11 in experimental Pseudomonas Aeruginosa sepsis in immunocompromised animals. J. Infect. Dis. 178,1205–1208.

    CAS  PubMed  Google Scholar 

  113. Fiorucci S., Antonelli E., Migliorati G., Santucci L., Morelli O., Federici B., and Morelli A. (1998) TNF-alpha processing enzyme inhibitors prevent aspirin-induced TNF-alpha release and protect against gastric mucosal injury in rats. Ailment Pharmacol. Ther. 12, 1139–1153.

    CAS  Google Scholar 

  114. Grover R., Zaccardelli D., Colice G., Guntupalli K., Watson D., and Vincent J. L. (1999) An open-label dose escalation study of the nitric oxide synthase inhibitor, N(G)-methyl-L-arginine hydrochloride (546C88), in patients with septic shock. Glaxo Wellcome International Septic Shock Study Group. Crit. Care Med. 27, 913–922.

    CAS  PubMed  Google Scholar 

  115. Eisele B., Lamy M., Thijs L. G., Keinecke H. O., Schuster H. P., Matthias F. R., et al. (1998) Antithrombin III in patients with severe sepsis. A randomized, placebo-controlled, double-blind multicenter trial plus a meta-analysis on all ran-domized, placebo-controlled, double-blind trials with antithrombin III in severe sepsis. Intensive Care Med. 24, 663–672.

    CAS  PubMed  Google Scholar 

  116. Pernerstorfer T., Hollenstein U., Hansen J., Knechtelsdorfer M., Stohlawetz P., Graninger W., et al. (1999) Heparin blunts endotoxin-induced coagulation activation. Circulation 100, 2485–2490.

    CAS  PubMed  Google Scholar 

  117. de Jonge E., Dekkers P. E., Creasey A. A., Hack C. E., Paulson S. K., Karim A., et al. (2000) Tissue factor pathway inhibitor dose-dependently inhibits coagulation activation without influencing the fibrinolytic and cytokine response during human endotoxemia. Blood 95,1124–1129.

    PubMed  Google Scholar 

  118. Fein A. M., Bernard G. R., Criner G. J., Fletcher E. C., Good J. T., Jr., Knaus, W. A., et al. (1997) Treatment of severe systemic inflammatory response syndrome and sepsis with a novel bradykinin antagonist, deltibant (CP-0127). Results of a randomized, double-blind, placebo-controlled trial. CP-0127 SIRS and Sepsis Study Group. JAMA 277,482–487.

    Google Scholar 

  119. Tani T., Hanasawa K., Endo Y., Yoshioka T., Kodama M., Kaneko M., et al. (1998) Therapeutic apheresis for septic patients with organ dysfunction:hemoperfusion using a polymyxin B immobilized column. Artif. Organs. 22, 1038–1044.

    CAS  PubMed  Google Scholar 

  120. Gillan E. R., Christensen R. D., Suen Y., Ellis R., van de Ven C., and Cairo M. S. (1994) A randomized, placebo-controlled trial of recombinant human granulocyte colony-stimulating factor administration in newborn infants with presumed sepsis: significant induction of peripheral and bone marrow neutrophilia. Blood 84, 1427–1433.

    CAS  PubMed  Google Scholar 

  121. Smith W. S., Sumnicht G. E., Sharpe R. W., Samuelson D., and Millard F. E. (1995) Granulocyte colony-stimulating factor versus placebo in addition to penicillin G in a randomized blinded study of gram-negative pneumonia sepsis: analysis of survival and multisystem organ failure. Blood 86, 1301–1309.

    CAS  PubMed  Google Scholar 

  122. Schedel I., Dreikhausen U., Nentwig B., Hockenschnieder M., Rauthmann D., Balikcioglu S., et al. (1991) Treatment of gram-negative septic shock with an immunoglobulin preparation: a prospective, randomized clinical trial. Crit. Care Med. 19, 1104–1113.

    CAS  PubMed  Google Scholar 

  123. Alejandria M. M., Lansang M. A., Dans L. F., and Mantaring J. B. (2000) Intravenous immunoglobulin for treating sepsis and septic shock. Cochrane Database Syst. Rev. 2, CD001090.

    Google Scholar 

  124. American College of Chest Physicians (1992) Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Society for Critical Care Medicine Consensus Conference. Crit. Care Med. 20, 864–875.

    Google Scholar 

  125. Jafari H. S. and McCracken G. H., Jr. (1992) Sepsis and septic shock: a review for clinicians. Pediatr. Infect. Dis. J. 11,739–748.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pediatrics, Imperial College School of Medicine, London, UK

    Simon Nadel, Iain Macintosh & Michael Levin

Authors
  1. Simon Nadel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Iain Macintosh
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Michael Levin
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. BC Research Institute for Children’s and Women’s Health, Vancouver, BC, Canada

    Andrew J. Pollard MD, PhD

  2. Wellcome Trust Centre for the Epidemiology of Infectious Disease, Oxford, UK

    Martin C. J. Maiden PhD

Rights and permissions

Reprints and permissions

Copyright information

© 2001 Humana Press Inc., Totowa, NJ

About this protocol

Cite this protocol

Nadel, S., Macintosh, I., Levin, M. (2001). Evaluation of New Treatments for Meningococcal Disease. In: Walker, J.M., Pollard, A.J., Maiden, M.C.J. (eds) Meningococcal Disease. Methods in Molecular Medicine™, vol 67. Humana Press. https://doi.org/10.1385/1-59259-149-3:549

Download citation

  • DOI: https://doi.org/10.1385/1-59259-149-3:549

  • Publisher Name: Humana Press

  • Print ISBN: 978-0-89603-849-3

  • Online ISBN: 978-1-59259-149-7

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics

Search

Navigation